SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-040856
Filing Date
2023-11-14
Accepted
2023-11-14 11:35:05
Documents
62
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1003261
2 ex31-1.htm EX-31.1 10885
3 ex31-2.htm EX-31.2 10491
4 ex32.htm EX-32 4466
  Complete submission text file 0001493152-23-040856.txt   4468443

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20230930.xsd EX-101.SCH 35585
6 XBRL CALCULATION FILE pvct-20230930_cal.xml EX-101.CAL 46506
7 XBRL DEFINITION FILE pvct-20230930_def.xml EX-101.DEF 137125
8 XBRL LABEL FILE pvct-20230930_lab.xml EX-101.LAB 275499
9 XBRL PRESENTATION FILE pvct-20230930_pre.xml EX-101.PRE 220762
56 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 663766
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 231402821
SIC: 2834 Pharmaceutical Preparations